Carmine Therapeutics And Takeda Pharmaceuticals Join Hands In A US$900M Research Alliance
Carmine Therapeutics and Takeda will collaborate to discover and develop non-viral Rare Disease Gene Therapies Using Carmine’s novel REGENT platform U.S. headquartered Biotech startup Carmine Therapeutics has signed a $900 million research collaboration agreement with Takeda Pharmaceutical to discover, develop and commercialize transformative non-viral gene therapies for two rare disease targets, according to a company […]
Carmine Therapeutics and Takeda will collaborate to discover and develop non-viral Rare Disease Gene Therapies Using Carmine’s novel REGENT platform U.S. headquartered Biotech startup Carmine Therapeutics has signed a $900 million research collaboration agreement with Takeda Pharmaceutical to discover, develop and commercialize transformative non-viral gene therapies for two rare disease targets, according to a company



